drugset / Trial / NCT07399470
A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.
RandomizedCrossoverOpen-labelOther
Summary
Bioequivalence study for the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg under fasting conditions in healthy volunteers
Timeline
- Start
- 2026-01-09
- Primary completion
- 2026-02-28
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |
| Subject | Gemigliptin | Small molecule | 50 mg | — |
| Subject | Metformin | Small molecule | 1000 mg | — |
Indications
No indication recorded.